Telix Pharmaceuticals Limited

Thank you for joining Telix at the American Urological Association #AUA24 Annual Meeting in San Antonio, Texas. We were pleased to host two Product Theaters, delving into Telix’s innovative theranostic programs in urology. These sparked meaningful conversations about the future of kidney cancer detection and management and the role of PSMA imaging in the initial staging of prostate cancer. The Meeting also featured several Telix related oral presentations, updating urologists on advancements in 68Ga-PSMA-11 and developments in the ProstACT Global Phase III study of TLX591, Telix’s first-in-class investigational PSMA-targeting radio antibody-drug conjugate therapy for prostate cancer. TLX591 has not received a marketing authorization in any jurisdiction.

Telix has today announced an agreement with Cardinal Health for the global clinical supply of actinium-225 (Ac-225), a therapeutic radioisotope that will be used in developing the Company’s alpha therapy pipeline. Alpha therapies are widely regarded as the next generation of radiopharmaceuticals, and a priority focus area for Telix’s therapeutic pipeline expansion. Their high energy output and short penetration depth compared with beta emitters may be more suited to treating smaller or disseminated tumours, and micro-metastatic disease. Learn more on our website: https://bit.ly/3y6zcb7

We are excited to partner with AMTAR, a hub which will accelerate the development and commercialisation of novel radiopharmaceuticals in Australia. This team of high-quality industry, academic and other research partners will enable the translational science required to bring these innovative new technologies to patients. Read about AMTAR and Telix’s research collaboration with the Australian Institute for Bioengineering and Nanotechnology AIBN at The University of Queensland below. Dr. James Wood and Dr. Saikat Ghosh, PhD share insights into the partnership and highlight the value of interdisciplinary collaboration and the importance of industry-academia partnerships in advancing radiopharmaceutical research. 

Gallium-68 imaging of prostate-specific membrane antigen (PSMA) - a protein that is overexpressed on the surface of prostate cancer cells and is low or absent on most normal healthy cells - provides a flexible and reliable option for the diagnosis of prostate cancer. This site from our friends at Cardinal Health explains how and why gallium doses arrive on time 99% of the time, giving physicians the confidence they need to guide their patient management decisions. Visit here: www.gallium68.com

Telix social media has “gone grey” for May. Despite advances in research, treatment options for many primary brain tumours are limited and the prognosis for patients remains poor. Brain Tumour Awareness Month offers an opportunity to highlight the challenges faced by patients and the important work that is being done to overcome these. A core focus area at Telix is developing therapeutic and diagnostic solutions for gliomas, which make up approximately 30% of all brain and central nervous system tumours and 80% of all malignant brain tumours. To learn more about our investigational theranostic brain cancer portfolio visit: telixpharma.com/brain Brain Tumour Alliance Australia (BTAA) Cure Brain Cancer Foundation Mark Hughes Foundation Cancer Council Australia Peace of Mind Foundation American Brain Tumor Association International Brain Tumour Alliance

Thank you for joining Telix at the Australian and New Zealand Society of Nuclear Medicine ASM 2024 in Christchurch, NZ. As the premier event for nuclear medicine in Australia and New Zealand we were pleased to have Telix’s investigational therapeutic and diagnostic assets, along with Illuccix® (68Ga-PSMA-11), featured in oral presentations across the weekend. Our Hosted Breakfast offered participants the opportunity to explore the latest advances in prostate cancer care from Telix’s lead radio antibody-drug conjugate (rADC) therapy candidate, to mobile PET and AI-enhanced imaging. We again had the privilege to support nurses from the Prostate Cancer Foundation of Australia, NeuroEndocrine Cancer Australia and Peter MacCallum Cancer Centre to attend a specialised workshop, equipping them with the tools and knowledge to support patients at every step of their journey in theranostic radiopharmaceuticals.

Telix today announces the completion of the acquisition of QSAM Biosciences Inc. and its lead investigational drug, Samarium-153-DOTMP. The asset is a novel kit-based bone-seeking targeted radiopharmaceutical with the dual potential applications of pain management of bone metastases and osteosarcoma therapy. This validated technology gives Telix a complementary and early commercial entry-point for its prostate cancer therapy franchise, further enhancing and differentiating our innovation position to provide a continuum of care to patients from diagnosis and staging, through systemic treatment of metastatic disease, to palliative care. Read more here: https://lnkd.in/gfJGfviS

Later this week, Telix will be attending the largest gathering of urologists worldwide at the American Urological Association's 2024 Annual Meeting in San Antonio, Texas. The ProstACT GLOBAL Phase III study of TLX591, Telix’s first-in-class investigational PSMA-targeting radio antibody-drug conjugate therapy for prostate cancer, will be featured as an oral presentation, alongside a series of presentations on Telix’s approved PSMA-PET imaging agent, Illuccix®. Come meet the team at booth #631 to discuss Telix’s theranostic programs in urology and join the discussion on the future of kidney cancer detection and management, and PSMA imaging for the initial staging of prostate cancer through two thought leadership sessions at the AUA Product Theater (booth #1159). To learn more about Telix’s presence at AUA and to secure your seat at the theater visit: https://bit.ly/3WnY34q TLX591 has not received a marketing authorisation in any jurisdiction.

Telix is live at #ANZSNM2024 in Christchurch, New Zealand! Come and meet the team at booths #29 & #30 to learn about our extensive theranostic pipeline and opportunities for collaboration. More on our presence here: https://lnkd.in/gsgy3Z_2

Nurses play a pivotal role in cancer care and, accordingly, Telix is pleased to once again support the Nurses Workshop at the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting 2024. In collaboration with nurses from Prostate Cancer Foundation of Australia, NeuroEndocrine Cancer Australia and Peter MacCallum Cancer Centre, join us as we explore crucial topics including: ⚛️ Understanding radiopharmaceuticals and tumour microenvironment effects – Michael Wheatcroft, Telix Chief Scientist. 🙃 How to navigate side effects: Tips and tricks featuring insights from Liz Medhurst (Prostate) and Kate Wakelin (NETs). 🤝 Working within a multidisciplinary team: Managing patients from pre- to post-imaging and therapy – Liz Medhurst. 💉 Difficult conversations: Addressing patient selection, treatment challenges, and expectations – Kate Wakelin. The session is open to all attendees. More info here: https://bit.ly/4baZS94